SCHEMBL8091793

SCHEMBL8091793

NCC(NS(=O)(=O)c1ccc(Cl)cc1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 14/20 0.63
ADAMTS5 Q9UNA0 1/20 0.63
SLC1A3 P43003 1/20 0.60
SLC1A2 P43004 1/20 0.60
SLC1A1 P43005 1/20 0.60
MMP9 P14780 11/20 0.54
MMP13 P45452 3/20 0.54
MMP1 P03956 2/20 0.54
MMP3 P08254 1/20 0.54
MMP7 P09237 1/20 0.54
CA2 P00918 2/20 0.51
MMP8 P22894 2/20 0.51
CA1 P00915 1/20 0.51
ADAMTS4 O75173 2/20 0.51
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
CA14 Q9ULX7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7654716 0.98 MMP2 (0.61) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL8839423 0.86 MMP2 (0.64) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL8839436 0.86 MMP2 (0.64) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL6500230 0.85 MMP2 (0.61) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL383079 0.85 MMP2 (0.61) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL1876081 0.85 MMP2 (0.60) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL14608753 0.84 MMP2 (0.53) MMP2ADAMTS5MMP9MMP13MMP1
SCHEMBL7099492 0.84 MMP2 (0.63) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1
SCHEMBL4041728 0.84 TDP1 (0.63) MMP2SLC1A3SLC1A2SLC1A1MMP9
SCHEMBL7370003 0.84 MMP2 (0.72) MMP2ADAMTS5SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1051625-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES Du Pont Pharmaceuticals Company (US) 2000-11-15 EP disclosed
WO-1999038014-A1 ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES DU PONT PHARMACEUTICALS COMPANY (US) 1999-07-29 WO disclosed